 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of acute liver [0m
[34minjury?[0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does MINOCYCLINE increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes MINOCYCLINE increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does MINOCYCLINE increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"MINOCYCLINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: MINOCYCLINE: warnings_and_cautions: This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. Enamel hypoplasia has [0m
[31malso been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT. C. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula [0m
[31mgrowth rate has been observed in premature human infants given oral tetracycline in doses of [0m[1;31m25[0m[31m mg/kg every [0m[1;31m6[0m[31m hours. This reaction was shown to be reversible when the drug was discontinued. Results of[0m
[31manimal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can cause retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has [0m
[31mbeen noted in animals treated early in pregnancy [0m[31m [0m[1;31m5[0m[31m. MINOCYCLINE: warnings_and_cautions: [0m[1;31m2[0m[31m Pseudomembranous Colitis Clostridium difficile associated diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m has been reported with nearly all [0m
[31mantibacterial agents, including minocycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to [0m
[31movergrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as [0m
[31mthese infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical [0m
[31mhistory is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed [0m
[31magainst C. difficile may need to be discontinued. MINOCYCLINE: warnings_and_cautions: Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and [0m
[31msurgical evaluation should be instituted as clinically indicated. [0m[1;31m5.3[0m[31m Hepatotoxicity Post-marketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic [0m
[31mfailure [0m[1;31m([0m[31msometimes fatal[0m[1;31m)[0m[31m have been reported with minocycline use in the treatment of acne. [0m[1;31m5.4[0m[31m Metabolic Effects The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this[0m
[31mis not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline-class drugs may lead to azotemia, hyperphosphatemia, and [0m
[31macidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. MINOCYCLINE: warnings_and_cautions: [0m
[31mUnder such conditions, lower than usual total doses are indicated, and if therapy is prolonged, serum level determinations of the drug may be advisable. [0m[1;31m5.5[0m[31m Central Nervous System Effects Central [0m
[31mnervous system side effects including light-headedness, dizziness or vertigo have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving [0m
[31mvehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually rapidly disappear when the drug is discontinued. [0m[1;31m5.6[0m[31m Benign Intracranial [0m
[31mHypertension Pseudotumor cerebri [0m[1;31m([0m[31mbenign intracranial hypertension[0m[1;31m)[0m[31m in adults and adolescents has been associated with the use of tetracyclines. Minocycline has been reported to cause or precipitate [0m
[31mpseudotumor cerebri, the hallmark of which is papilledema. Clinical manifestations include headache and blurred vision. MINOCYCLINE: warnings_and_cautions: Bulging fontanels have been associated with [0m
[31mthe use of tetracyclines in infants. Although signs and symptoms of pseudotumor cerebri resolve after discontinuation of treatment, the possibility for permanent sequelae such as visual loss that may [0m
[31mbe permanent or severe exists. Patients should be questioned for visual disturbances prior to initiation of treatment with tetracyclines. If visual disturbance occurs during treatment, patients should[0m
[31mbe checked for papilledema. Concomitant use of isotretinoin and minocycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. [0m[1;31m5.7[0m[31m Autoimmune [0m
[31mSyndromes Tetracyclines have been associated with the development of autoimmune syndromes. The long-term use of minocycline in the treatment of acne has been associated with drug-induced lupus-like [0m
[31msyndrome, autoimmune hepatitis and vasculitis. MINOCYCLINE: warnings_and_cautions: Sporadic cases of serum sickness have presented shortly after minocycline use. Symptoms may be manifested by fever, [0m
[31mrash, arthralgia, and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. Use of all tetracycline-class drugs [0m
[31mshould be discontinued immediately. [0m[1;31m5.8[0m[31m Photosensitivity Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been [0m
[31mreported rarely with minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight [0m[1;31m([0m[31mtanning beds or UVA/B treatment[0m[1;31m)[0m[31m while using minocycline. If patients need to be [0m
[31moutdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. [0m[1;31m5[0m[31m. MINOCYCLINE: [0m
[31mwarnings_and_cautions: [0m[1;31m9[0m[31m Serious Skin/Hypersensitivity Reaction Cases of anaphylaxis, serious skin reactions [0m[1;31m([0m[31me.g. Stevens Johnson syndrome[0m[1;31m)[0m[31m, erythema multiforme, and drug rash with eosinophilia and [0m
[31msystemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m syndrome have been reported postmarketing with minocycline use in patients with acne. DRESS syndrome consists of cutaneous reaction [0m[1;31m([0m[31msuch as rash or exfoliative dermatitis[0m[1;31m)[0m[31m, [0m
[31meosinophilia, and one or more of the following visceral complications such as: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. Fever and lymphadenopathy may be present. In some [0m
[31mcases, death has been reported. If this syndrome is recognized, the drug should be discontinued immediately. [0m[1;31m5.10[0m[31m Tissue Hyperpigmentation Tetracycline class antibiotics are known to cause [0m
[31mhyperpigmentation. MINOCYCLINE: warnings_and_cautions: Tetracycline therapy may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity [0m
[1;31m([0m[31mteeth, mucosa, alveolar bone[0m[1;31m)[0m[31m, sclerae and heart valves. Skin and oral pigmentation has been reported to occur independently of time or amount of drug administration, whereas other tissue [0m
[31mpigmentation has been reported to occur upon prolonged administration. Skin pigmentation includes diffuse pigmentation as well as over sites of scars or injury. [0m[1;31m5.11[0m[31m Development of Drug Resistant [0m
[31mBacteria Bacterial resistance to the tetracyclines may develop in patients using minocycline hydrochloride extended-release tablets, therefore, the susceptibility of bacteria associated with infection[0m
[31mshould be considered in selecting antimicrobial therapy. Because of the potential for drug-resistant bacteria to develop during the use of minocycline hydrochloride extended-release tablets, it should[0m
[31mbe used only as indicated. [0m[1;31m5[0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS • The use of minocycline hydrochloride extended-release tablets during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and [0m
[31mchildhood up to the age of [0m[1;31m8[0m[31m years[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m • If pseudomembranous colitis occurs, discontinue minocycline hydrochloride [0m
[31mextended-release tablets. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m • If liver injury is suspected, discontinue minocycline hydrochloride extended-release tablets. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m • If renal impairment exists, minocycline hydrochloride [0m
[31mextended-release tablets doses may need to be adjusted to avoid excessive systemic accumulations of the drug and possible liver toxicity. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m • Minocycline may cause central nervous system side [0m
[31meffects including light-headedness, dizziness, or vertigo. Advise [0m[1;31mpatients.[0m[1;31m([0m[31m [0m[1;31m5[0m[31m. MINOCYCLINE: warnings_and_cautions: [0m[1;31m5[0m[31m [0m[1;31m)[0m[31m • Minocycline may cause pseudotumor cerebri [0m[1;31m([0m[31mbenign intracranial hypertension[0m[1;31m)[0m[31m [0m
[31min adults and adolescents. Discontinue minocycline hydrochloride extended-release tablets if symptoms [0m[1;31moccur.[0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m • Minocycline has been associated with autoimmune syndromes; discontinue minocycline[0m
[31mhydrochloride extended-release tablets immediately if symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m • Minocycline has been associated with anaphylaxis, serious skin reactions, erythema multiforme, and DRESS syndrome. [0m
[31mDiscontinue minocycline hydrochloride extended-release tablets immediately if symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.9[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m Teratogenic Effects A. MINOCYCLINE, LIKE OTHER TETRACYCLINE-CLASS DRUGS, CAN CAUSE FETAL HARM [0m
[31mWHEN ADMINISTERED TO A PREGNANT WOMAN. MINOCYCLINE: warnings_and_cautions: IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD [0m
[31mBE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS. Minocycline hydrochloride extended-release tablets should not be used during pregnancy or by individuals of either gender who are attempting to [0m
[31mconceive a child [0m[31m. B. THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT [0m[1;31m([0m[31mLAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD UP TO THE AGE OF [0m[1;31m8[0m[31m YEARS[0m[1;31m)[0m[31m MAY CAUSE PERMANENT DISCOLORATION OF[0m
[31mTHE TEETH [0m[1;31m([0m[31mYELLOW-GRAY-BROWN[0m[1;31m)[0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: package_ndc         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_set_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: adverse_reactions: Table [0m[1;31m2[0m[31m: Selected Treatment-Emergent Adverse Reactions in at least [0m[1;31m1[0m[31m% of Clinical Trial Subjects Adverse Reactions Minocycline Hydrochloride Extended-Release [0m
[31mTablets [0m[1;31m([0m[1;31m1[0m[31m mg/kg[0m[1;31m)[0m[31m [0m[31mN[0m[31m=[0m[1;31m674[0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Placebo [0m[31mN[0m[31m=[0m[1;31m364[0m[1;31m([0m[31m%[0m[1;31m)[0m[31m At least one treatment-emergent event [0m[1;31m379[0m[1;31m([0m[1;31m56[0m[1;31m)[0m[31m [0m[1;31m197[0m[1;31m([0m[1;31m54[0m[1;31m)[0m[31m Headache [0m[1;31m152[0m[31m [0m[1;31m([0m[1;31m23[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m [0m[1;31m([0m[1;31m23[0m[1;31m)[0m[31m Fatigue [0m[1;31m62[0m[31m [0m[1;31m([0m[1;31m9[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m7[0m[1;31m)[0m[31m Dizziness [0m[1;31m59[0m[31m [0m[1;31m([0m[1;31m9[0m[1;31m)[0m[31m [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m Pruritus [0m[1;31m31[0m[31m [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m Malaise[0m
[1;31m26[0m[31m [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m Mood alteration [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m Somnolence [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Urticaria [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m Tinnitus [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Arthralgia [0m[1;31m9[0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m2[0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m MINOCYCLINE: adverse_reactions: Vertigo [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Dry mouth [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m
[1;31m5[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Myalgia [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m6.2[0m[31m Postmarketing Experience Adverse reactions that have been reported with minocycline hydrochloride use in a variety of indications include: Skin and hypersensitivity [0m
[31mreactions: fixed drug eruptions, balanitis, erythema multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity [0m
[31mreactions, angioneurotic edema, anaphylaxis, DRESS syndrome [0m[31m. Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient [0m
[31mlupus-like syndrome. MINOCYCLINE: adverse_reactions: Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing. Endocrine: brown-black microscopic thyroid [0m
[31mdiscoloration, abnormal thyroid function. Oncology : thyroid cancer. Oral: glossitis, dysphagia, tooth discoloration. Gastrointestinal : enterocolitis, pancreatitis, hepatitis, liver failure. Renal : [0m
[31mreversible acute renal failure. Hematology : hemolytic anemia, thrombocytopenia, eosinophilia. Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis[0m
[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_patient_package_insert: See “What should I tell my doctor before taking minocycline hydrochloride extended-release tablets?” • Intestine infection [0m[1;31m([0m[31mpseudomembranous colitis[0m[1;31m)[0m[31m.[0m
[31mPseudomembranous colitis can happen with most antibiotics, including minocycline hydrochloride extended-release tablets. Call your doctor right away if you get watery diarrhea, diarrhea that does not [0m
[31mgo away, or bloody stools. • Serious liver problems . Stop taking minocycline hydrochloride extended-release tablets and call your doctor right away if you get any of the following symptoms of liver [0m
[31mproblems: ∘ loss of appetite ∘ tiredness ∘ diarrhea ∘ yellowing of your skin or the whites of your eyes ∘ unexplained bleeding ∘ confusion ∘ sleepiness • Central nervous system effects. See “What [0m
[31mshould I avoid while taking minocycline hydrochloride extended-release tablets? MINOCYCLINE: spl_patient_package_insert: Central nervous system effects such as light headedness, dizziness, and a [0m
[31mspinning feeling [0m[1;31m([0m[31mvertigo[0m[1;31m)[0m[31m may go away during your treatment with minocycline hydrochloride extended-release tablets or if treatment is stopped. • Benign intracranial hypertension, also called [0m
[31mpseudotumor cerebri . This is a condition where there is high pressure in the fluid around the brain. This swelling may lead to vision changes and permanent vision loss. Stop taking minocycline [0m
[31mhydrochloride extended-release tablets and tell your doctor right away if you have blurred vision, vision loss, or unusual headaches. Immune system reactions including a lupus-like syndrome, [0m
[31mhepatitis, and inflammation of blood or lymph vessels [0m[1;31m([0m[31mvasculitis[0m[1;31m)[0m[31m. Using minocycline hydrochloride extended-release tablets for a long time to treat acne may cause immune system reactions. Tell your [0m
[31mdoctor right away if you get a fever, rash, joint pain, or body weakness. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to check your blood for immune system reactions. • Serious [0m
[31mrash and allergic reactions . Minocycline hydrochloride extended-release tablets may cause a serious rash and allergic reactions that may affect parts of your body such as your liver, lungs, kidneys [0m
[31mand heart. Sometimes these can lead to death. MINOCYCLINE: spl_patient_package_insert: • Stop taking minocycline hydrochloride extended-release tablets and get medical help right away if you have any [0m
[31mof these symptoms: ∘ skin rash, hives, sores in your mouth, or your skin blisters and peels ∘ swelling of your face, eyes, lips, tongue, or throat ∘ trouble swallowing or breathing ∘ blood in your [0m
[31murine ∘ fever, yellowing of the skin or the whites of your eyes, dark colored urine ∘ pain on the right side of the stomach area [0m[1;31m([0m[31mabdominal pain[0m[1;31m)[0m[31m ∘ chest pain or abnormal heartbeats ∘ swelling in your[0m
[31mlegs, ankles and feet ∘ darkening of your nails, skin, eyes, scars, teeth, and gums. The most common side effects of minocycline hydrochloride extended-release tablets include: • headache • tiredness [0m
[31m• dizziness or spinning feeling • itching Call your doctor if you have a side effect that bothers you or that does not go away. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to [0m
[31mcheck you for side effects during treatment with minocycline hydrochloride extended-release tablets. These are not all the side effects with minocycline hydrochloride extended-release tablets. Ask [0m
[31myour doctor or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to Sandoz Inc. at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How [0m
[31mshould I store minocycline hydrochloride extended-release tablets? • Store minocycline hydrochloride extended-release tablets at 20º to 25ºC [0m[1;31m([0m[31m68º to 77ºF[0m[1;31m)[0m[31m [0m[31m. • Keep minocycline hydrochloride [0m
[31mextended-release tablets in the container that it comes in and keep container tightly closed. • Keep minocycline hydrochloride extended-release tablets dry.         [0m
[31mSOURCE:MINOCYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Yes, MINOCYCLINE has been associated with an increased risk of acute liver injury. Post-marketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant [0m
[32mhepatic failure [0m[1;32m([0m[32msometimes fatal[0m[1;32m)[0m[32m, have been reported with MINOCYCLINE use in the treatment of acne.[0m

[32mSOURCE: MINOCYCLINE label[0m
[32mEXTRACT_START_END: Hepatotoxicity Post-marketing cases of serious liver injury[0m[32m...[0m[32m fulminant hepatic failure [0m[1;32m([0m[32msometimes fatal[0m[1;32m)[0m[32m have been reported[0m[32m...[0m
*[1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Yes, MINOCYCLINE has been associated with an increased risk[0m
[34mof acute liver injury. Post-marketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic failure [0m[1;34m([0m[34msometimes fatal[0m[1;34m)[0m[34m, have been reported with MINOCYCLINE [0m
[34muse in the treatment of acne.[0m

[34mSOURCE: MINOCYCLINE label[0m
[34mEXTRACT_START_END: Hepatotoxicity Post-marketing cases of serious liver injury[0m[34m...[0m[34m fulminant hepatic failure [0m[1;34m([0m[34msometimes fatal[0m[1;34m)[0m[34m have been reported[0m[34m...[0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if MINOCYCLINE increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler confirmed that MINOCYCLINE has been associated with an increased risk of acute liver injury, including cases of serious liver injury, irreversible drug-induced hepatitis, and [0m
[32mfulminant hepatic failure, some of which have been fatal."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"MINOCYCLINE has been associated with an increased risk of acute liver injury."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does MINOCYCLINE increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if MINOCYCLINE increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler confirmed that MINOCYCLINE has been associated with an increased risk of acute liver injury, including cases of serious liver injury, irreversible drug-induced hepatitis, and [0m
[34mfulminant hepatic failure, some of which have been fatal."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"MINOCYCLINE has been associated with an increased risk of acute liver injury."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does MINOCYCLINE increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if MINOCYCLINE increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler confirmed that MINOCYCLINE has been associated with an increased risk of acute liver injury, including cases of serious liver injury, irreversible drug-induced hepatitis, and fulminant [0m
[31mhepatic failure, some of which have been fatal.[0m
[31m        -----[0m
[31m        Final answer: MINOCYCLINE has been associated with an increased risk of acute liver injury.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mMINOCYCLINE has been associated with an increased risk of acute liver injury. This includes reports of serious liver injury, irreversible drug-induced hepatitis, and fulminant hepatic failure, some of[0m
[32mwhich have been fatal, as confirmed by FDAHandler referencing the MINOCYCLINE label.[0m
